| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-08-18 | Medivir (Sweden) Ascletis (China) | MIV-802 | hepatitis C | licensing | Infectious diseases | Licensing agreement |
| 2017-08-16 | Abcam (UK) TTP Labtech (UK) | reagent kits for the quantification of secreted proteins | collaboration - research - R&D | Technology - Services | Collaboration agreement | |
| 2017-08-11 | Oxford Biomedica (UK) Cell and Gene Therapy Catapult (UK) Stratophase (UK) Synthace (UK) | gene and cell therapy manufacturing | collaboration | Technology - Services | Collaboration agreement | |
| 2017-08-10 | Reprocell (Japan) Reprocell Europe (UK) | Reprocell Centre for Predictive Drug Discovery | opening of new premises | Technology - Services | Opening of new premises | |
| 2017-08-03 | Regeneron Pharmaceuticals (USA - NY) Sanofi (France) | fully human therapeutic antibodies | development - commercialisation | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Dermatological diseases | Termination of an agreement | |
| 2017-08-02 | Biophytis (France) | nomination | Ageing diseases - Muscle disorders - Ophtalmological diseases | Nomination | ||
| 2017-07-31 | Onxeo (France) Vectans Pharma (France) | Sitavig® (acyclovir Lauriad™), Loramyc® (miconazole Lauriad™) | labial herpes, oropharyngeal candidiasis | product acquisition | Infectious diseases | Product acquisition |
| 2017-07-27 | Galapagos (Belgium) Servier (France) | small molecule candidate drugs including GLPG1972/S201086 | osteoarthritis | R&D development licensing | Rheumatic diseases - Inflammatory diseases – Bone diseases | Exercise of an option agreement |
| 2017-07-27 | Takeda Pharmaceutical (Japan) Tesaro (US - MA) | niraparib | licensing - devlopment - commercialisation | Cancer - Oncology | Licensing agreement | |
| 2017-07-27 | AstraZeneca (UK) Merck&Co (USA - NJ) | Imfinzi® (durvalumab), Keytruda® (pembrolizumab), Lynparza® (olaparib), selumetinib | collaboration - development | Cancer - Oncology | Collaboration agreement | |
| 2017-07-26 | Emergent BioSolutions (USA - MD) Valneva (France - Austria) | ZIKV-VLA1601 | Zika virus infection | licensing - collaboration | Infectious diseases | Licensing agreement |
| 2017-07-24 | Eli Lilly (USA - IN) Nektar Therapeutics (USA - CA) | NKTR-358 | development - commercialisation | Autoimmune diseases – Inflammatory diseases | Development agreement | |
| 2017-07-24 | Seattle Genetics (USA - WA) Genentech, a member of Roche Group (USA - CA - Switzerland) | SGN-LIV1A and atezolizumab | triple-negative breast cancer (TNBC) | clinical research | Cancer - Oncology | Clinical research agreement |
| 2017-07-20 | Roche (Switzerland) Oryzon Genomics (Spain) | inhibitors of Lysine Specific Demethylase-1 (LSD1; KDM1A) including ORY-1001 (RG6016) | acute myeloid leukaemia | research - development - licensing | Cancer - Oncology | Termination of an agreement |
| 2017-07-20 | Recipharm (Sweden) LIDDS (Sweden) | Liproca®Depot | prostate cancer | production - manufacturing | Cancer - Oncology | Production agreement |
| 2017-07-20 | Emergent BioSolutions (USA - MD) GSK (UK) | raxibacumab | anthrax | product acquisition | Infectious diseases | Product acquisition |
| 2017-07-19 | GSK (UK) | UK manufacturing network | restructuring | Infectious diseases - Respiratory diseases | Restructuring | |
| 2017-07-18 | Novimmune (Switzerland) Baxalta (USA - IL) now Shire (UK - USA) | novel bispecific antibodies based on kappa-lambda bispecific antibody technology | hemophilia A | R&D - research | Rare diseases - Genetic diseases - Hematological diseases | Research agreement |
| 2017-07-18 | 4SC (Germany) Maruho (Japan) | inhibitor of the Kv1.3 ion channel | licensing | Autoimmune diseases - Dermatological diseases | Licensing agreement | |
| 2017-07-17 | BiogenIdec (USA - MA) Isis Pharmaceuticals , now Ionis Pharmaceuticals (USA - CA) | antisense therapies for neurological diseases | neurological diseases, neuromuscular diseases | development | Neurological diseases - Neuromuscular diseases | Milestone |
